Kodiak Sciences (NASDAQ:KOD) Price Target Raised to $5.00 at HC Wainwright

Kodiak Sciences (NASDAQ:KOD) had its target price hoisted by HC Wainwright from $3.00 to $5.00 in a research note released on Monday morning,Benzinga reports. HC Wainwright currently has a neutral rating on the stock.

Several other equities analysts have also issued reports on KOD. Barclays raised their price target on Kodiak Sciences from $4.00 to $7.00 and gave the stock an “underweight” rating in a research report on Thursday. JPMorgan Chase & Co. upgraded Kodiak Sciences from an “underweight” rating to a “neutral” rating and set a $15.00 price target on the stock in a research report on Thursday, August 14th.

Kodiak Sciences Stock Up 6.4%

NASDAQ:KOD opened at $11.25 on Monday. The business’s 50-day moving average price is $5.72 and its two-hundred day moving average price is $4.44. Kodiak Sciences has a twelve month low of $1.92 and a twelve month high of $11.60. The stock has a market cap of $594.23 million, a P/E ratio of -2.96 and a beta of 2.41.

Kodiak Sciences (NASDAQ:KOD) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.02). On average, equities research analysts expect that Kodiak Sciences will post -3.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Kodiak Sciences

Large investors have recently made changes to their positions in the business. Headlands Technologies LLC grew its position in shares of Kodiak Sciences by 256.4% in the 2nd quarter. Headlands Technologies LLC now owns 8,083 shares of the company’s stock worth $30,000 after buying an additional 5,815 shares during the last quarter. US Bancorp DE grew its position in shares of Kodiak Sciences by 131.7% in the 1st quarter. US Bancorp DE now owns 9,282 shares of the company’s stock worth $26,000 after buying an additional 5,276 shares during the last quarter. Vontobel Holding Ltd. bought a new stake in shares of Kodiak Sciences in the 1st quarter worth approximately $28,000. Jump Financial LLC bought a new stake in shares of Kodiak Sciences in the 4th quarter worth approximately $147,000. Finally, Public Employees Retirement System of Ohio grew its position in shares of Kodiak Sciences by 183.9% in the 4th quarter. Public Employees Retirement System of Ohio now owns 14,759 shares of the company’s stock worth $147,000 after buying an additional 9,560 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.